Study of AT-527 in Subjects With Normal and Impaired Renal Function

Inclusion Criteria

• •Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
• •Females must have a negative pregnancy test at Screening and prior to dosing
• •BMI of 18.5 to 42.0 kg/m2
• •Willing to comply with the study requirements and to provide written informed consent
• •Subjects with Normal Renal Function (Group E):
• •Medically healthy, in the opinion of an Investigator
• •Normal renal function with eGFR ≥ 90 mL/min/1.73m2 at Screening
• •Renal Impaired Subjects (Groups A, B, and C):
• •Considered stable in the judgement of an Investigator
• •Presence of severe renal impairment (eGFR ≥ 15 and \< 30 mL/min/1.73m2), moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min/1.73m2) or mild renal impairment (eGFR ≥ 60 and \< 90 mL/min/1.73m2) at Screening: renal impairment should have been stable for at least 1 month prior to Screening.
• •Subjects with End-Stage Renal Disease -ESRD (Group D)
• •Considered clinically stable in the opinion of the Investigator
• •Presence of ESRD (eGFR \<15 mL/min/1.73m2 and being on intermittent hemodialysis) at Screening and have been stable for at least 1 month prior to Screening